Second-Line Treatment Options for Patients with Recurrent Cervical Cancer. Review of Current Treatment and Future Directions-Webinar Recording - Second-Line Treatment Options for Patients with Recurrent Cervical Cancer. Review of Current Treatment and Future Directions

Webinar Recording - Second-Line Treatment Options for Patients with Recurrent Cervical Cancer. Review of Current Treatment and Future Directions

Back to course

Video Transcription

Video Summary

The video summarizes the advancements and developments in cervical cancer science. The speaker highlights the efforts of the International Gynecologic Cancer Society (IGCS) in providing educational opportunities and treatment options for gynecologic oncology professionals. They emphasize the importance of optimizing patient care, both locally and globally. The speaker encourages viewers to provide feedback and suggests using the IGCS Education 360 Learning Portal for educational resources.<br /><br />The speaker discusses three components that have contributed to the progress in cervical cancer treatment: bevacizumab, pembrolizumab, and antibody drug conjugates (ADCs). They show data from clinical trials on the efficacy of these treatments in terms of overall survival, progression-free survival, and response rates. They also discuss the safety profiles of these treatments.<br /><br />The speaker mentions ongoing trials exploring the use of pembrolizumab and ADCs in combination with chemotherapy, as well as in neoadjuvant, concomitant, and adjuvant settings. They address questions about treatment options for small cell carcinoma and the use of PD-L1 inhibitors in PD-L1 negative patients.<br /><br />Overall, the video highlights the significant advancements and potential of novel treatments in improving outcomes for patients with cervical cancer.

Keywords

cervical cancer science

advancements

IGCS

treatment options

clinical trials

efficacy

safety profiles

novel treatments